Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients

被引:14
作者
Ohuchi, Kentaro [1 ]
Kambayashi, Yumi [1 ]
Hidaka, Takanori [1 ]
Fujimura, Taku [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi, Japan
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
melanoma; PAI-1; TAMs; Anti-PD1; Abs; efficacy; MACROPHAGES; PROMOTES; CELLS;
D O I
10.3389/fonc.2021.798385
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plasminogen activating inhibitor-1 (PAI-1) plays crucial roles in the development of various cancers, including melanomas. Indeed, various pro-tumorigenic functions of PAI-1 in cancer progression and metastasis have been widely reported. Among them, PAI-1 is also reported as a key regulator of PD-L1 expression on melanoma cells through endocytosis, leading to abrogating the efficacy of anti-PD1 antibodies (Abs). These findings suggested that PAI-1 expression might predict the efficacy of anti-PD1 Abs. In this report, the expression and production of PAI-1 in melanoma patients were evaluated, and the immunomodulatory effects of PAI-1 on tumor-associated macrophages were investigated in vitro. Immunohistochemical staining of PAI-1 showed that PAI-1 expression on melanoma cells was significantly decreased in responders compared to non-responders. Moreover, baseline serum levels of PAI-1 were significantly decreased in responders compared to non-responders. Notably, PAI-1 decreased the production of various chemokines from monocyte-derived M2 macrophages in vitro, suggesting that PAI-1 might decrease tumor-infiltrating lymphocytes to hamper the anti-tumor effects of anti-PD1 Abs. These results suggest that baseline serum levels of PAI-1 may be useful as a biomarker for identifying patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma
    Amini-Adle, M.
    Khanafer, N.
    Le-Bouar, M.
    Duru, G.
    Dalle, S.
    Thomas, L.
    BMC CANCER, 2018, 18
  • [32] Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
    Pires da Silva, Ines
    Zakria, Danny
    Ahmed, Tasnia
    Trojanello, Claudia
    Dimitriou, Florentia
    Allayous, Clara
    Gerard, Camille
    Zimmer, Lisa
    Lo, Serigne
    Michielin, Olivier
    Lebbe, Celeste
    Mangana, Johanna
    Ascierto, Paolo Antonio
    Johnson, Douglas B.
    Carlino, Matteo
    Menzies, Alexander
    Long, Georgina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
  • [33] Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma
    M. Amini-Adle
    N. Khanafer
    M. Le-Bouar
    G. Duru
    S. Dalle
    L. Thomas
    BMC Cancer, 18
  • [34] SDCBP modulates tumor microenvironment, tumor progression and anti-PD1 efficacy in colorectal cancer
    Yu, Jiahua
    Yu, Shijun
    Bai, Jin
    Zhu, Zhe
    Gao, Yong
    Li, Yandong
    CANCER GENE THERAPY, 2024, 31 (05) : 755 - 765
  • [35] Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma
    Jing-jing Li
    Jiu-hong Wang
    Ya Dingv
    Dan-dan Li
    Xi-zhi Wen
    Jing-jing Zhao
    Hang Jiang
    Xing Liu
    Fu-xue Huang
    Xiao-shi Zhang
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 1159 - 1169
  • [36] Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
    Babacan, Nalan Akgul
    Eroglu, Zeynep
    CURRENT ONCOLOGY REPORTS, 2020, 22 (04)
  • [37] Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study
    Xiong, Jianping
    Ouyang, Weiwei
    Yang, Mengxiang
    Gao, Zhenyuan
    Zhou, Huan
    Lou, Hanmei
    Guo, Yabing
    Xu, Zhongyuan
    Zheng, Ling
    Liu, Ying
    Wang, Zhongfeng
    Sun, Ping
    Niyazi, Huerxidan
    Wang, Jianhua
    Chen, Yan
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    Guo, Weijian
    ADVANCES IN THERAPY, 2024, 41 (11) : 4153 - 4171
  • [38] Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
    Lee, J. H.
    Long, G. V.
    Boyd, S.
    Lo, S.
    Menzies, A. M.
    Tembe, V.
    Guminski, A.
    Jakrot, V.
    Scolyer, R. A.
    Mann, G. J.
    Kefford, R. F.
    Carlino, M. S.
    Rizos, H.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1130 - 1136
  • [39] Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients
    Heidelberger, Valentine
    Goldwasser, Francois
    Kramkimel, Nora
    Jouinot, Anne
    Huillard, Olivier
    Boudou-Rouquette, Pascaline
    Chanal, Johan
    Arrondeau, Jennifer
    Franck, Nathalie
    Alexandre, Jerome
    Blanchet, Benoit
    Leroy, Karen
    Avril, Marie-Francoise
    Dupin, Nicolas
    Aractingi, Selim
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (04) : 436 - 441
  • [40] Complete responses to two different anti-PD1 agents in a metastatic melanoma patient
    Kilickap, Saadettin
    Guven, Deniz C.
    Aktepe, Oktay H.
    Aktas, Burak Y.
    Dizdar, Omer
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (02) : 496 - 499